Case Western Reserve University signed an exclusive license agreement with Picture Health to develop AI technologies to help predict, diagnose, and treat lung cancer.
Combination immunotherapy with the anti-PD-L1 monoclonal antibody durvalumab and other novel agents outperforms durvalumab alone in the neoadjuvant (pre-surgical) setting for early-stage non-small-cell lung cancer, researchers from The University of Texas MD Anderson Cancer Center reported at the 2022 AACR annual meeting.
A retrospective, observational study sponsored by G1 Therapeutics described the burden of myelosuppression and its impact on healthcare resource utilization in 3,277 patients being treated with chemotherapy for extensive-stage small-cell lung cancer. The study also described patient outcomes from 21 patients receiving Cosela (trilaciclib) prior to chemotherapy.
Genentech announced that the phase III SKYSCRAPER-02 study, evaluating the investigational anti-TIGIT immunotherapy tiragolumab plus Tecentriq (atezolizumab) and chemotherapy (carboplatin and etoposide) as a first-line treatment for extensive-stage small cell lung cancer (ES-SCLC), did not meet its co-primary endpoint of progression-free survival.
Davey Daniel was appointed chief medical officer of OneOncology on Feb. 7, succeeding Lee Schwartzberg, who will remain a senior advisor to the company.
Yale Cancer Center researchers have identified novel oncogenic gene fusions in lung and pancreatic cancer, as well as sarcoma. The fusions involve RASGRF1 (an activator of RAS signaling) and promote cellular changes leading to tumor development.
Jhanelle Gray was named chair of the SWOG Cancer Research Network’s Lung Cancer Committee, effective April 1.
ALK Positive and LUNGevity Foundation have issued a Request for Application for ALK-positive Lung Cancer Research Awards to be granted in 2022.
The FY22 Defense Appropriations Act is anticipated to provide funding for the Lung Cancer Research Program to support high-impact lung cancer research.
A team of researchers with the UC Davis Comprehensive Cancer Center found that even with expanded access to Medi-Cal health coverage, Latino smokers in California continue to get less help than non-Latino white people quitting smoking.
